Aquestive Therapeutics is trading 8.9% up at $4.71, outperforming its recent closes as biotechnology shares rally on positive Moderna cancer-vaccine trial results.
- No fresh company-specific announcement was identified for August 19, 2026.
- Recent support includes completed Anaphylm studies and the planned Q3 2026 FDA resubmission.
- Second-quarter revenue rose 38% year over year to $13.8 million.